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Abstract
Renal cell carcinomas arise from the nephron but are heterogeneous in disease biology,
clinical behavior, prognosis, and response to systemic therapy. Development of patient-
specific in vitromodels that efficiently and faithfully reproduce the in vivo phenotype may
provide a means to develop personalized therapies for this diverse carcinoma. Studies to
maintain and model tumor phenotypes in vitro were conducted with emerging three-dimen-
sional culture techniques and natural scaffolding materials. Human renal cell carcinomas
were individually characterized by histology, immunohistochemistry, and quantitative PCR
to establish the characteristics of each tumor. Isolated cells were cultured on renal extracel-
lular matrix and compared to a novel polysaccharide scaffold to assess cell-scaffold interac-
tions, development of organoids, and maintenance of gene expression signatures over time
in culture. Renal cell carcinomas cultured on renal extracellular matrix repopulated tubules
or vessel lumens in renal pyramids and medullary rays, but cells were not observed in glo-
meruli or outer cortical regions of the scaffold. In the polysaccharide scaffold, renal cell car-
cinomas formed aggregates that were loosely attached to the scaffold or free-floating within
the matrix. Molecular analysis of cell-scaffold constructs including immunohistochemistry
and quantitative PCR demonstrated that individual tumor phenotypes could be sustained
for up to 21 days in culture on both scaffolds, and in comparison to outcomes in two-dimen-
sional monolayer cultures. The use of three-dimensional scaffolds to engineer a personal-
ized in vitro renal cell carcinoma model provides opportunities to advance understanding of
this disease.
Introduction
Kidney cancer is one of the ten most common malignancies in the United States and is increas-
ing in frequency, due in part to greater prevalence of putative risk factors including smoking,
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obesity, and hypertension, as well as increased detection resulting from improvements in diag-
nostic imaging [1]. Within the broad classification of kidney cancers, renal cell carcinoma
(RCC) accounts for approximately 85% of all cases and greater than 90% of all renal malignan-
cies. The annual financial burden for treating RCC is over $4 billion in the United States alone
and continues to rise with over 60,000 new cases diagnosed annually [2]. This diverse group of
cancers includes clear cell, papillary, chromophobe, collecting duct, and medullary subtypes
and is associated with challenges in defining prognosis and in predicting response to therapy.
The RCC subtypes share the nephron as a common site of origin but differ in disease biology,
clinical behavior, prognosis, and response to therapy [3]. At present, the RCC subtypes can be
distinguished histologically but identification of specific biomarkers for screening, diagnosis,
and to predict therapeutic response would significantly improve treatment approaches and
outcomes. Development of patient-specific in vitro organoid models for RCC that efficiently,
faithfully, and economically reproduce the in vivo phenotype are essential for the development
of targeted, personalized therapies for this diverse group of cancers.
In vitro studies of RCC are challenging due to the complex three-dimensional (3D) architec-
ture of the kidney. The current standard for RCC culture involves primary [4–6] or immortal-
ized cells grown on conventional two-dimensional (2D) tissue culture plastic. In many
instances, the phenotype of the parental tumor from which a 2D cell line has been established
is unknown, or the culture fails to maintain the primary phenotype over time [7]. Issues of
validity in 2D in vitro studies are not unique to RCC, but also pose challenges in studies to pre-
dict the success or failure of new drug candidates and to predict nephrotoxicity [8, 9]. Emerg-
ing 3D culture methods will likely improve the ability to model tumor behavior in culture as
this technique provides a supportive milieu although scaffolds that can support growth and the
nascent phenotype are needed [10–14].
Our studies have previously demonstrated that decellularized kidneys of all age groups pro-
vide a natural extracellular matrix (ECM) with sufficient structural properties to support
migration of cells from kidney explants to repopulate the scaffold in an age-dependent manner
[15], and the ability to provide spatial and organizational influences on human embryonic
stem cell migration and differentiation [16–18]. The goals of the current study were to: (1)
develop improved 3D scaffold and culture methods for the in vitro study of RCC, and (2) assess
scaffold support of RCC organoids with maintenance of the parental tumor phenotype. These
studies demonstrate that individual tumor phenotypes could be maintained under the 3D cul-
ture conditions as described, and that the scaffolds provide a means to support the growth and
development of organoids with the same phenotypic features of the parental tumor.
Materials and Methods
Specimens
No human subjects were involved in the study. The UC Davis Comprehensive Cancer Center,
which is funded by the National Cancer Institute (NCI), has a biorepository that provides
anonymized specimens to investigators through university approved practices and protocols
(http://www.ucdmc.ucdavis.edu/cancer/research/sharedresources/specimen.html). No animal
subjects were involved in the study. A biorepository of previously obtained decellularized rhe-
sus monkey kidney sections were used for these studies; kidneys were obtained through the tis-
sue procurement program (www.cnprc.ucdavis.edu/our-services).
The UC Davis Comprehensive Cancer Center's Biorepository Shared Resource provides
high quality, well-characterized cancer-related human tissue specimens and biological materi-
als to researchers. Anonymized resected tumor sections (N = 25) and corresponding non-
tumor (distal to the tumor) (N = 22) specimens were obtained. Specimens collected were used
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for primary cell cultures, snap frozen in liquid nitrogen for molecular analysis, and sections
collected in 10% buffered formalin.
Primary Cultures
Specimens were finely minced under sterile conditions in endothelial growth medium (EGM2;
Lonza, Walkersville, MD), which we have previously shown in preliminary studies to support
the growth of multiple renal cell phenotypes in culture (data not shown). Minced tissue was
then dissociated by incubation with collagenase Type IV (5 mg/ml, Life Technologies, Grand
Island, NY) at 37°C for 40 to 50 minutes with vortexing at 10 minute intervals. Specimens were
maintained at a size that could be transferred with a serological pipette, then additional medium
was added (1:1 ratio) to halt the dissociation process. Following centrifugation, the supernatant
containing collagenase was discarded and the cell pellet re-suspended in EGM2 for culture on
standard tissue-culture dishes (Sigma-Aldrich, St. Louis, MO). Medium was changed at 3-day
intervals once cells were adherent (48–72 hours) and cultures maintained at 37°C, 5% CO2 until
80% confluent. Cultures were then utilized for 3D experiments (passage 0–2).
RT-PCR Tumor Gene Panel
Fresh tissues snap-frozen in liquid nitrogen were used to isolate RNA with the AllPrep DNA/
RNAmini kit (Qiagen, Valencia, CA) and cDNA prepared following DNase I treatment (Qia-
gen) with random primers (Ambion, Life Technologies) and the Sensiscript Reverse Transcrip-
tase kit (Qiagen). NextBio (www.nextbio.com), a repository of data from genomic studies and
patient molecular profiles, was used to assess potential markers for RT-PCR analysis. The mark-
ers selected from NextBio included: Carbonic anhydrase 9 (CA9), Egl nine homolog 3
(EGLN3), Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3),
Fatty acid binding protein 7 (FABP7), KISS1-derived peptide receptor (KISS1R), Lysyl oxidase
(LOX), and Neuronal pentraxin 2 (NPTX2). This panel of markers was expanded to include the
renal stem and progenitor cell markers Octamer-binding transcription factor 4 (OCT4), Oxida-
tive-stress responsive 1 (OSR1), Sine oculis homeobox homolog 1 (SIX1), and Sine oculis
homeobox homolog 1 (SIX2). RT-PCR was performed to assess the expression of these markers
in tumor and non-tumor samples. The housekeeping gene, Glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) was used as the internal control for CA9, EGLN3, ENPP3, FABP7, LOX,
and NPTX2, which were assessed with Taqman probe-based RT-PCR (Life Technologies). Elon-
gation factor-1 alpha (EF1α) was used as the internal control for OCT4, OSR1, SIX1, and SIX2,
which were assessed with SYBR Green dye-based RT-PCR (Qiagen) and primer sets published
previously [13]. Relative gene expression was compared with the ΔΔCT method utilizing normal
human kidney cDNA prepared from human kidney total RNA (Life Technologies).
3D Organoid Culture
Two 3D scaffolds were used: stored rhesus monkey decellularized sections of renal scaffolds
(renal ECM) [15] and a polysaccharide scaffold (PSS) (GroCell-3D, Molecular Matrix Inc.,
Davis, CA). As previously shown, the renal ECM retained the vascular, tubular, and glomerular
compartments of the native kidney with removal of greater than 99% of all other non-ECM
proteins including collagenase. The PSS contains pores of an approximate 200-μm diameter
and 500–700 μm in length (S1 Fig). Due to size and quality limitations of the resected speci-
mens received, cells were plated in 2D to allow expansion prior to plating on 3D scaffolds. Low
passage (0–2) cells from individual tumor or non-tumor cultures (from each individual speci-
men) were seeded on scaffolds in order to create a unique and personalized cell-scaffold con-
struct. Standard 2D cultures on tissue culture plastic were utilized as cell culture controls. Cells
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from each resected tumor or cells distal to the tumor were plated (approximately 1x106 cells/8
mm scaffold diameter) by gently applying cells to the scaffold surface in 20-μl aliquots of
medium. Cell-scaffold constructs composed of tumor or non-tumor from a given specimen
were cultured in 24-well plates for 5±1 hours to allow cell adherence prior to addition of
EGM2. Medium was changed at 3-day intervals throughout the culture period.
Analysis of Cell-Scaffold Constructs
Cell-scaffold constructs were collected at 1, 2, or 3-week intervals and fixed in 10% buffered
formalin for 4 hours, transferred to 70% ethanol, then processed for paraffin embedding. Paraf-
fin blocks were exhaustively sectioned at 5-μm thickness for histological analysis. At 10-section
intervals, additional formalin-fixed, paraffin-embedded (FFPE) sections were collected for
molecular analysis by changing sectioning thickness to 10 μm and collecting two sections in
microcentrifuge tubes for PCR. Tubes for molecular analysis were stored at-80°C until
processing.
Construct Histological Analysis
For each cell-scaffold construct, every 10th section was stained with hematoxylin and eosin
(H&E) to assess cell infiltration and morphology. Sections were viewed with an Olympus BX61
microscope (Olympus, Center Valley, PA) and images captured with MetaMorph Image Anal-
ysis Software (Molecular Devices, Sunnyvale, CA). Morphology of cells within scaffolds was
characterized as: (1) non-adherent or loosely attached organoids, (2) adherent, epithelial-like
cells lining edges and lumens, or (3) single cells. Immunohistochemistry was performed on
selected adjacent sections for Cytokeratin (wide-spectrum, rabbit polyclonal, Abcam) and
Vimentin (mouse monoclonal V9, Sigma-Aldrich) following previously established protocols
[13]. Staining for the RCC antigen was also conducted according to established protocols [14].
Construct Molecular Analysis
DNA and RNA were isolated from FFPE sections using the AllPrep DNA/RNA FFPE kit (Qia-
gen). Isolated RNA was treated with DNase I (Qiagen) to eliminate potential DNA contamina-
tion prior to downstream analysis. cDNA was synthesized using random primers (Ambion,
Life Technologies) and the Sensiscript Reverse Transcriptase kit (Qiagen). For each tumor, sig-
nature genes found to be upregulated from normative range kidney standards were identified
by the tumor gene panel screen and utilized to monitor cell phenotype over time in 2D and 3D
cultures. PCR for selected markers was carried out with appropriate SYBR or Taqman assay
protocols as described above. Relative changes in gene expression were analyzed by the com-
parative ΔΔCT method normalized to the cells on the day of seeding.
Statistical Analysis
Results of qPCR gene expression analysis were expressed as the mean ± standard error of the
mean (SEM). A multivariate analysis of variance (MANOVA) was conducted on log-trans-
formed gene expression data to assess the following relationships: tumor samples versus nor-
mal human kidney standards; tumor samples versus non-tumor samples from the same
kidney; and to test for differences of tumor subtype. When the MANOVA was significant,
posthoc t-tests were used to assess significance of changes in gene expression for individual
genes. The chi-squared test was used to assess significant differences in the frequency of epithe-
lial or organoid outcomes in cell-scaffold constructs.
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Results
Patient Demographics
The gender, age, and racial demographics of individuals from which anonymized specimens
were received (N = 25 tumor, N = 22 non-tumor site) are summarized in Table 1. Patients ran-
ged in age from 31 to 85 years (mean 61 years, median 59 years).
RCC Subtype and Histopathology Distribution
Clinical pathology reports for each tumor were provided by the UC Davis Comprehensive
Cancer Center and are summarized in Table 2. Specimens included the three most common
RCC subtypes: clear cell (60%), papillary (24%), and chromophobe (4%); and correlated with
reported population frequencies of these subtypes [19–21]. Nearly 50% of the tumors were
classified as pT1a with 16% as pT2a. Mean tumor size at resection was 5.1 cm with a range of
0.9 to 12.0 cm. More than half of the tumors (60%) were less than 5.0 cm in size. The predomi-
nant Fuhrman nuclear grade was 2 (40%) followed by 3 (15%) and 1 (12%). H&E staining indi-
cated the specimens were representative of the expected morphology for each RCC subtype.
Non-tumor specimens from the same kidneys were frequently observed with atypical histopa-
thology including hypercellularity and the presence of epithelial nests. Immunohistochemistry
was completed on FFPE sections to further characterize the phenotype of each specimen. Cyto-
keratin and vimentin co-expression was observed in 70% of tissues and was not correlated with
a specific RCC subtype. Remaining specimens were vimentin-positive and cytokeratin-nega-
tive. In non-tumor specimens, vimentin staining was noted in mesangial cells of the glomeruli
with cytokeratin staining found in some, but not all, tubules. Double-positive cells were typi-
cally not observed in non-tumor tissues with the exception of the parietal epithelium of Bow-
man’s capsule and rare tubule segments. A subset of specimens evaluated (9/10) expressed
RCC antigen with varied intensity that was not correlated with tumor subtype. Proximal
tubules of non-tumor tissues also routinely stained positive for RCC antigen (data not shown).
RCCGene Expression
Tumor and non-tumor specimens from each case were screened with a panel of markers previ-
ously identified to be upregulated in RCC. An initial search for a gene upregulated (3-fold
increase in gene expression compared with non-tumor kidney specimens) across all cases was
explored with the goal of identifying a single marker that could be used to assess the presence
of RCC over time in culture. Relative gene expression data from individual samples was highly
variable with no single gene consistently upregulated across cases or within an RCC subtype.
Genes upregulated with the greatest frequency included CA9 (59.1%), NPTX2 (54.5%), and
Table 1. Demographics.
Sex N Race / Ethnicity N
Male 18 (72%) White, non-Hispanic 18 (72%)
Female 7 (32%) Black / African-American 1 (4%)
Age (Years) N American Indian / Alaska Native 1 (4%)
45 2 (8%) Asian 2 (8%)
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KISS1R (40.9%). When averaged across specimens, expression increased in RCC samples for
all genes in the panel except LOX, which was downregulated. The genes upregulated greater
than 5-fold compared with control kidney standards included CA9, EGLN3, FABP7, KISS1R,
NPTX2, OCT4, and SIX1. These genes, with the exception of KISS1R and NPTX2, were also
upregulated in non-tumor samples from RCC-affected kidneys (Fig 1). Differences in gene
expression across all cases when comparing tumor and non-tumor samples were not statisti-
cally significant with the exception of CA9 and LOX (p<0.05). Given the RCC heterogeneity
demonstrated in these results, two to four markers were selected specific to each case as a
unique and personalized “signature” for in vitro analysis of 3D constructs engineered with cells
from a given tumor.
RCC In vitro Cultures
Primary cultures were established from 20/25 tumor specimens and 22/22 non-tumor samples.
Those specimens associated with poor derivation of cell culture included a predominance of
adipose or necrotic regions in the sample. In general, dissociated cells from non-tumor samples
attached to the plate surface and grew more rapidly than cells from RCC in primary 2D cul-
tures. When cultured in 3D scaffolds, RCC proliferation was observed at week 1 with continued
growth and expansion evident over the 3-week culture period. Sections of 3D constructs were
analyzed by H&E to assess cell frequency, location, morphology, and to compare with initial
specimen histology (Fig 2A). Morphology and location of RCC in the renal ECM scaffold was
consistent across all specimens with cells observed as individual, epithelial-like cells in the
medullary regions or lining tubules or vessel lumens in renal pyramids and medullary ray loca-
tions. RCC consistently failed to repopulate glomeruli or cortical tubules of renal ECM scaf-
folds. In contrast, the morphology of RCC cultured in the PSS included organoid aggregates as
a predominant feature, with some cells found lining lumens in an epithelial-like arrangement.
Organoid aggregates were observed in the PSS in both tumor (89%) and non-tumor (75%) con-
structs but typically larger in size when cells from the RCC were used (Fig 3). The RCC orga-
noids were frequently free-floating or loosely attached to the PSS lattice and were not observed
to form in renal ECM scaffolds.
Table 2. Renal Cell Carcinoma (RCC) Subtype and Classification.
RCC Subtype N Tumor Grade N
Clear Cell 15 (60%) 1 3 (12%)
Papillary 6 (24%) 2 10 (40%)
Chromophobe 1 (4%) 3 4 (16%)
Oncocytoma 2 (8%) 4 2 (8%)
Mixed 1 (4%) ND 6 (24%)
Classification N Size (cm) N
pT1a 12 (48%) < 5 15 (60%)
pT1b 2 (8%)  5 to < 7 2 (8%)
pT2a 4 (16%)  7 to < 10 4 (16%)
pT2b 1 (4%)  10 3 (12%)
pT3a 2 (8%) ND 1 (4%)
ND 4 (16%)
Mixed: Separate foci of clear cell and papillary RCC noted; Size: Range 0.9 to 12.0 cm, Mean 5.1 cm,
Median 3.9 cm
ND = not determined.
doi:10.1371/journal.pone.0136758.t002
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RCC Phenotype in 3D Constructs: Immunohistochemistry
The molecular phenotype of RCC within the scaffolds was assessed by immunohistochemistry
for cytokeratin, vimentin, and RCC antigen and compared with expression in the correspond-
ing tumor or non-tumor specimens from which cells were derived (Fig 2B). The cytokeratin /
vimentin staining pattern of the parental tumor was typically maintained in 3D constructs
although cytokeratin expression was observed more frequently in cells on renal ECM than in
the PSS. Notably, cells from non-tumor samples were frequently double positive for cytokeratin
and vimentin in 3D cultures with both scaffold types despite the presence of few double posi-
tive cells observed in the parental sample. RCCMarker expression was reduced in 3D cultures
compared with parental tumor or non-tumor samples, but maintained more frequently in the
PSS constructs (80%) than renal ECM constructs (50%).
RCC Phenotype in 3D Constructs: Gene Expression
Genes upregulated in individual RCC specimens were selected to monitor the phenotype by
RT-PCR in 3D cell-scaffold constructs. Expression of tumor signature genes was consistently
maintained in 3D cultures for up to 21 days, with loss of expression of tumor genes noted in 2D
culture conditions (Fig 4). For a given RCC, differences in gene expression were not detected
between renal ECM and the PSS. FABP7 expression was not maintained in vitro under any cul-
ture conditions tested suggesting that additional substrates or growth factors may be necessary
to maintain expression of this gene. When non-tumor cells were plated on 3D scaffolds, expres-
sion patterns were similar to RCC from the same kidney suggesting that a small population of
tumor cells with a proliferative advantage thrived in 3D culture from the non-tumor sample.
Discussion
The barriers to development of more effective treatment regimens for RCC include a lack of dis-
tinguishing biomarkers, subtype differences, heterogeneity of underlying acquired or hereditary
genetic mutations, and inter-patient diversity [22, 23]. These factors also complicate in vitro stud-
ies of tumor biology and drug development, and highlight the need for new strategies to address
Fig 1. Relative gene expression in RCC tumor and non-tumor samples.Gene expression relative to normal human kidney cDNA was calculated from
RCC tumor (N = 22) and non-tumor (N = 18) samples and presented as the mean ± standard error of the mean (SEM); *p<0.05. Relative to grossly normal
kidney, all genes were upregulated more than 2-fold except for LOX (downregulated) and SIX2 (upregulated 1.4 fold) in tumor samples. Expression was also
upregulated in non-tumor samples for many genes. Differences between tumor and non-tumor samples were not significant with the exception of CA9 and
LOX (p<0.05).
doi:10.1371/journal.pone.0136758.g001
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Fig 2. Phenotypic comparison of 3D RCC-scaffold constructs with parental tumor characteristics. A. Hematoxylin and eosin (H&E) staining of
parental tissue and corresponding RCC 3D constructs with renal ECM or polysaccharide scaffolds (PSS). Representative examples shown include clear cell
(a-c) and papillary (d-f) RCC subtypes. Tumor (g-i) and non-tumor (j-l) tissue and 3D constructs from a single clear cell RCC-affected kidney are also shown.
Regardless of tumor subtype, RCC typically repopulated medullary regions of the renal ECM, specifically the pyramids and medullary rays. RCC in the PSS
were predominantly found as heterogeneous organoids (black arrows) that were free-floating within, or loosely attached to, the scaffold. B.
Immunohistochemical staining for vimentin (green), cytokeratin (red), and the RCCMarker (brown). Representative examples are shown from clear cell
tumor (a-c) and non-tumor (d-f) tissue from the same kidney; and papillary (g-i), and clear cell (j-l) RCC. Co-expression of cytokeratin and vimentin (white
arrows) was noted in 70% of parental tumor tissues with remaining tissues vimentin-positive. Tumor-derived cell-scaffold constructs typically expressed the
cytokeratin / vimentin staining pattern of the parental tissue, although increased vimentin expression was noted on renal ECM. Co-expression of these
markers was only observed in parietal epithelial cells of Bowman’s capsule in histologically normal non-tumor tissues. In rare instances, non-tumor tissues
3D Culture of Renal Cell Carcinomas
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these issues. In vitro 3D culture conditions for RCC which faithfully reproduce the molecular
and histological phenotype of the parental tumor more precisely than standard 2D culture condi-
tions, and which can be correlated with patient outcomes, may provide a solution for basic stud-
ies of tumor biology and to efficiently assess targeted and patient-specific personalized therapies.
Gene expression analysis can be a useful tool to provide insight into tumor biology, prognosis,
or to allow sub-grouping of a clinically diverse group of cancers for more effective treatment
strategies. Previous RCC gene expression studies have documented the heterogeneity in RNA
expression across samples and identified various sets of 20+ genes with potential predictive
power to recognize aggressive, metastatic tumors from less aggressive forms of the disease [24–
26]. To facilitate in vitro studies where maintenance of the cellular phenotype over time in cul-
ture is essential, we chose to identify a smaller set of select genes upregulated in individual sam-
ples as a personalized signature for a given tumor. With this method, a large gene panel can
effectively focus on a few signature genes, which uniquely represent a given tumor and can be
utilized to ensure individual cultures maintain the tumor phenotype over time and across studies.
Intra-tumor heterogeneity, as described in studies of gene expression in RCC biopsy samples
[27] or in terms of cell composition, was not assessed in this study and will be important to
understand in the context of in vitro culture in future studies. The resected specimens, while typi-
cally larger than a standard biopsy sample, were not inclusive of the entire tumor; future studies
will be necessary to assess the size of the specimen needed to accurately represent the bulk tumor
cell or gene expression profile. Similarly, initial 2D expansion was often necessary to isolate cells
from small specimens. Further studies to establish 3D tumor constructs directly from resected
specimens may provide additional insights regarding intra-tumor cellular heterogeneity.
contained tubules with double-positive cells (d). Strong RCCMarker (brown arrows) expression was observed in 90% of specimens, in proximal tubules of
non-tumor tissue, and was maintained in some, but not all, 3D RCC constructs (k, l). Scale bars = 100 μm.
doi:10.1371/journal.pone.0136758.g002
Fig 3. RCC organoid formation in 3D is dependent on scaffold type. Non-parametric characterization of cell morphology in 3D tissue engineered
constructs. Some constructs contained cells in more than one classification. Tumor (N = 15) and non-tumor (N = 8) cells were found as single cells or lining
some tubules of the renal pyramid and medullary rays in 3D cell-renal ECM constructs. In the 3D PSS constructs, tumor (N = 22) and non-tumor (N = 8) cells
were typically observed as loosely-attached organoid clusters, although some cells were found lining scaffold lumens. Scaffold impact on cell morphology
was significant (p<0.001).
doi:10.1371/journal.pone.0136758.g003
3D Culture of Renal Cell Carcinomas
PLOSONE | DOI:10.1371/journal.pone.0136758 August 28, 2015 9 / 13
Previous in vitro RCC studies have relied primarily on 2D monolayer cultures of primary or
immortalized cell lines [6]. While these cultures may retain DNA copy number profiles of the
parental tumor [28, 29], loss of cellular heterozygosity has been reported and relevance to the
in vivo setting is not reflected in the correlation of in vitro drug development or kidney toxicity
screens to patient outcomes [8]. Advances in tissue engineering with a focus on the kidney sug-
gest application of these 3D culture methods to studies on renal development or disease may
enhance in vitromodels by more closely recapitulating in vivo interactions with other cells and
ECMmolecules, therefore offering more opportunities for long-term culture maintenance. Sev-
eral groups have assessed 3D culture conditions for primary renal cells or RCC with various
substrates including small intestine submucosa [30] and Matrigel [31, 32], or as suspension cul-
tures of spheroid aggregates [9, 33, 34]. Tumor grafts of fresh human specimens implanted in
immunodeficient mice (“patient derived xenografts”) have been shown to retain the morphol-
ogy and characteristics of parental tumors [35] and have also been utilized to study specific
drug activity against RCC [7, 36]. Identifying new ways to utilize natural scaffolds and matrices
Fig 4. RCC gene expression signature is maintained over time in 3D, but not 2D, cultures. Relative expression of selected tumor signature genes in
tissue (tumor, non-tumor) and after 14 or 21 days in monolayer culture (2D plastic) or on 3D scaffolds (Renal ECM or PSS). PCR samples were run in
triplicate to ensure accuracy with appropriate PCR reagents and negative transcriptase controls. Representative examples are shown from papillary (A) and
clear cell (B, D) tumors, and non-tumor clear cell specimens (C). Because of the variation in gene expression signature from one biological replicate (e.g.,
patient sample) to the next, pooling of data was not appropriate. Instead, this analysis focused on the degree to which the original tumor or non-tumor gene
expression pattern was maintained over time in culture across all patients (N = 22 tumor, N = 8 non-tumor 3D cultures). In all cases, expression of the
signature gene set was more frequently maintained in 3D cultures. Differences in gene expression were not detected between renal ECM and the PSS.
Despite strong expression in tumor tissues, expression of FABP7 was not maintained with any culture condition tested.
doi:10.1371/journal.pone.0136758.g004
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that can demonstrate maintenance of the 3D architecture and cellular heterogeneity of tumor
biology will be important to accurately and efficiently assess drug responses [37]. Organoids,
which contain multiple organ-specific cell types and architectural similarities to the native
organ, have been developed from small intestine [10–12] and other organs including the kid-
ney [8, 9] and emphasize the importance of these in vitro culture systems to study effective
therapies specific to the patient and their disease. The development of 3D organoid protocols
for RCC provides an in vitro resource for studies on RCC in general and for drug development
and kidney toxicity screens in particular.
The ability of 3D scaffolds to support RCC growth and to maintain the phenotype over time
was assessed in this study with renal ECM from decellularized kidneys and a patented PSS.
These results indicate that the scaffold material significantly influences cell morphology but
does not impact gene expression signatures of individual tumors. Gene expression phenotypes
of individual RCC were typically lost in 2D cultures but could be maintained for up to 21 days
in 3D cultures as noted. Maintenance of a signature gene expression pattern was largely uni-
form across the heterogeneous set of tumors analyzed, with the exception of FABP7, a gene for
which expression was not maintained from any tumor or under any culture condition tested.
Although gene expression phenotypes were maintained with both 3D scaffolds, the orga-
noid nature of RCC growth in the PSS suggests this natural material may be more efficient for
long-term studies to assess interactions of stromal or non-tumor cells with malignant cells, and
as a tool to predict therapeutic responses. In contrast, the unique interaction of RCC with the
medullary components of the renal ECM suggests this interface may be valuable for future
studies of the metastatic origins of RCC, and specific tubular characteristics that may influence
tumor proliferation. Further development of 3D culture strategies will permit high throughput
opportunities to study patient-specific interactions of malignant cells with other cell types
within the niche including stromal, epithelial, and endothelial cells [7, 14, 32]. Patients with
advanced RCC that do not respond to standard chemotherapy may require more personalized
treatment, which targets different tumor subtypes as well as primary RCC. Three-dimensional
RCC in vitro models may provide a unique approach for developing and screening chemother-
apeutic agents that target all tumor subtypes. These in vitromodels may also reduce the num-
ber of in vivo studies required for drug development and screening.
The studies described herein demonstrate that RCC cell-scaffold 3D constructs are useful
for engineering personalized RCC in vitro models, and provide important opportunities for the
study of pathogenesis, progression, and drug screening that may improve outcomes for RCC
patients.
Supporting Information
S1 Fig. Scaffold morphology. A. Renal ECM from decellularized rhesus monkey kidney
retains tubular and vascular lumens as well as glomerular compartments. Scale bar = 100 μm.
B. SEM of polysaccharide scaffold (PSS) with pores connected of 500–700 μm. Scale
bar = 500 μm.
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